Philips Gets Warning Letter From US FDA on Device Facilities

Royal Philips NV received a letter from the US Food and Drug Administration warning that three manufacturing sites don’t meet standards, a blow to efforts to draw a line under high-profile issues with some of its products.

The medical equipment maker’s shares fell as much as 8.3% in Amsterdam trading, the most since April, and were 5.4% lower at 5 p.m.